GSK: indication for Arexvy extended in Japan

(CercleFinance.com) - GSK announces that the Japanese Ministry of Health has approved the extension of the indication for Arexvy, its respiratory syncytial virus (RSV) vaccine, to include adults aged 50 to 59 at increased risk.


Since September 2023, this vaccine had already been approved in Japan for adults aged 60 and over.

This decision was based on the results of a Phase III clinical trial, demonstrating non-inferior immunogenicity and consistent safety for this higher-risk age group.

The vaccine is currently approved in 35 countries for this population, and further regulatory decisions are pending.


Copyright (c) 2024 CercleFinance.com. All rights reserved.